Denise Clavijo-Cornejo

Denise Clavijo-Cornejo

Auto-generated profile, based on publicly available information

Denise Clavijo-Cornejo

Rheumatology Laboratory, National Institute of Rehabilitation Luis Guillermo Ibarra Ibarra, Tlalpan, CDMX, Mexico

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2013 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
CECristina Enriquez-Cortina
Cristina Enriquez-Cortina
MAMaylin Almonte-Becerril
Maylin Almonte-Becerril
DCDenise Clavijo-Cornejo
Denise Clavijo-Cornejo
MDMayrel Palestino Dominguez
Mayrel Palestino Dominguez
OBOscar Bello-Monroy
Oscar Bello-Monroy
Luis Gomez-QuirozLuis Gomez-Quiroz
Luis Gomez-Quiroz
The worldwide increment of multidrug- and extensively drug-resistant tuberculosis has emphasized the importance of looking for new options in therapeutics. Long-time usage or higher doses of isoniazid and rifampicin have been considered for the treatment of multidrug-resistant tuberculosis; however, the risk of liver failure is proportionally increased. Hepatocyte growth factor (HGF) is a multitask growth factor that stimulates both antiapoptotic and antioxidant responses that counteract the toxic effects of drug metabolism in the liver. The present work was focused to address the antioxidant and antiapoptotic effects of HGF on isoniazid- and rifampicin-induced hepatotoxicity. BALB/c mice were subjected to rifampicin (150mg/kg, intragavage [ig]) plus isoniazid (75mg/kg, ig) for 7 days. Increments in alanine aminotransferase activity, steatosis, apoptosis, and oxidative stress markers were found in animals. Recombinant HGF (iv) prevented all the harmful effects by increasing the activation of Erk1/2 and PKCδ signaling pathways and glutathione (GSH) synthesis. Furthermore, inhibition of endogenous HGF with anti-HGF antibody (iv) enhanced the isoniazid- and rifampicin-induced oxidative stress damage and decreased the GSH content, aggravating liver damage. In conclusion, HGF demonstrated to be a good protective factor against antituberculosis drug-induced hepatotoxicity and could be considered a good adjuvant factor for the use of high doses of or the reintroduction of these antituberculosis drugs.

1 January 2016 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
DCDenise Clavijo-Cornejo
Denise Clavijo-Cornejo
KMKarina Martínez-Flores
Karina Martínez-Flores
KSKarina Silva-Luna
Karina Silva-Luna
GMGabriela Angelica Martínez-Nava
Gabriela Angelica Martínez-Nava
JFJavier Fernández‐Torres
Javier Fernández‐Torres
ALAlberto López-Reyes
Alberto López-Reyes
Osteoarthritis is characterized by the presence of proinflammatory cytokines and reactive oxygen species. We aimed to clarify the role of prooxidant enzyme content at the synovial membrane level and how it correlates with the inflammatory process in patients with knee osteoarthritis (KOA). In synovial membranes from KOA patients and control group, we analyzed the protein content of prooxidant enzymes such as Nox2, xanthine oxidase (XO), and prolidase as well as the proinflammatory NALP3. Results show that protein content of prolidase and Nox2 increased 4.8‐ and 8.4‐fold, respectively, and XO showed an increasing trend, while the NALP3 inflammasome increased 5.4‐fold with respect to control group. Levels of prolidase and XO had a positive correlation between the levels of NALP3 and Nox2. By principal component analysis the protein expression pattern by study groups was evaluated. Three clusters were identified; protein expression patterns were higher for clusters two (prolidase) and three (XO and Nox2) between KOA patients and controls. Data suggest that prooxidant enzymes increase in synovial membrane of KOA patients and may contribute to the inflammatory state and degradation of the articular cartilage.

1 June 2013 in Biochimie
Verified
Journal Article
Closed access
DCDenise Clavijo-Cornejo
Denise Clavijo-Cornejo
CECristina Enriquez-Cortina
Cristina Enriquez-Cortina
ALAlberto López-Reyes
Alberto López-Reyes
Mayra Domínguez-PérezMayra Domínguez-Pérez
Mayra Domínguez-Pérez
NNNatalia Nuño-Lámbarri
Natalia Nuño-Lámbarri
Luis Gomez-QuirozLuis Gomez-Quiroz
Luis Gomez-Quiroz

1 January 2016 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
Mayra Domínguez-PérezMayra Domínguez-Pérez
Mayra Domínguez-Pérez
NNNatalia Nuño-Lámbarri
Natalia Nuño-Lámbarri
DCDenise Clavijo-Cornejo
Denise Clavijo-Cornejo
ALArmando Luna-López
Armando Luna-López
VSVerónica Souza
Verónica Souza
MGMaría Concepción Gutierrez-Ruiz
María Concepción Gutierrez-Ruiz
Cholesterol overload in the liver has shown toxic effects by inducing the aggravation of nonalcoholic fatty liver disease to steatohepatitis and sensitizing to damage. Although the mechanism of damage is complex, it has been demonstrated that oxidative stress plays a prominent role in the process. In addition, we have proved that hepatocyte growth factor induces an antioxidant response in hepatic cells; in the present work we aimed to figure out the protective effect of this growth factor in hepatocytes overloaded with free cholesterol. Hepatocytes from mice fed with a high‐cholesterol diet were treated or not with HGF, reactive oxygen species present in cholesterol overloaded hepatocytes significantly decreased, and this effect was particularly associated with the increase in glutathione and related enzymes, such asγ‐gamma glutamyl cysteine synthetase, GSH peroxidase, and GSH‐S‐transferase. Our data clearly indicate that HGF displays an antioxidant response by inducing the glutathione‐related protection system.

Verified
Journal Article
Open access
PDF file
SRSamuel Reyes-Long
Samuel Reyes-Long
JCJose Luis Cortés-Altamirano
Jose Luis Cortés-Altamirano
Cindy BandalaCindy Bandala
Cindy Bandala
KAKarina Avendaño-Ortiz
Karina Avendaño-Ortiz
HBHerlinda Bonilla-Jaime
Herlinda Bonilla-Jaime
AAAlfonso Alfaro-Rodriguez
Alfonso Alfaro-Rodriguez
The ongoing pandemic of COVID-19 has caused more than 6.7 million tragic deaths, plus, a large percentage of people who survived it present a myriad of chronic symptoms that last for at least 6 months; this has been named as long COVID. Some of the most prevalent are painful symptoms like headache, joint pain, migraine, neuropathic-like pain, fatigue and myalgia. MicroRNAs are small non-coding RNAs that regulate genes, and their involvement in several pathologies has been extensively shown. A deregulation of miRNAs has been observed in patients with COVID-19. The objective of the present systematic review was to show the prevalence of chronic pain-like symptoms of patients with long COVID and based on the expression of miRNAs in patients with COVID-19, and to present a proposal on how they may be involved in the pathogenic mechanisms of chronic pain-like symptoms. A systematic review was carried out in online databases for original articles published between March 2020 to April 2022; the systematic review followed the PRISMA guidelines, and it was registered in PROSPERO with registration number CRD42022318992. A total of 22 articles were included for the evaluation of miRNAs and 20 regarding long COVID; the overall prevalence of pain-like symptoms was around 10 to 87%, plus, the miRNAs that were commonly up and downregulated were miR-21-5p, miR-29a,b,c-3p miR-92a,b-3p, miR-92b-5p, miR-126-3p, miR-150-5p, miR-155-5p, miR-200a, c-3p, miR-320a,b,c,d,e-3p, and miR-451a. The molecular pathways that we hypothesized to be modulated by these miRNAs are the IL-6/STAT3 proinflammatory axis and the compromise of the blood–nerve barrier; these two mechanisms could be associated with the prevalence of fatigue and chronic pain in the long COVID population, plus they could be novel pharmacological targets in order to reduce and prevent these symptoms.

2 July 2019 in La radiologia medica
Verified
Journal Article
Closed access
PDF file
MGMarwin Gutierrez
Marwin Gutierrez
MTMarika Tardella
Marika Tardella
LRLuis Rodriguez
Luis Rodriguez
JMJaime Mendoza
Jaime Mendoza
DCDenise Clavijo-Cornejo
Denise Clavijo-Cornejo
CBChiara Bertolazzi
Chiara Bertolazzi